Biblio

Export 11 results:
Author [ Title(Asc)] Type Year
Filters: Author is Fagan, Anne M  [Clear All Filters]
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 
T
R. A. Sperling, Aisen, P. S., Beckett, L. A., Bennett, D. A., Craft, S., Fagan, A. M., Iwatsubo, T., Jack, C. R., Kaye, J., Montine, T. J., Park, D. C., Reiman, E. M., Rowe, C. C., Siemers, E., Stern, Y., Yaffe, K., Carrillo, M. C., Thies, B., Morrison-Bogorad, M., Wagster, M. V., and Phelps, C. H., “Toward defining the preclinical stages of Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease.”, Alzheimers Dement, vol. 7, no. 3, pp. 280-92, 2011.
S
S. L. Allison, Fagan, A. M., Morris, J. C., and Head, D., “Spatial Navigation in Preclinical Alzheimer's Disease.”, J Alzheimers Dis, vol. 52, no. 1, pp. 77-90, 2016.
P
P. Chatterjee, Lim, W. L. F., Shui, G., Gupta, V. B., James, I., Fagan, A. M., Xiong, C., Sohrabi, H. R., Taddei, K., Brown, B. M., Benzinger, T., Masters, C., Snowden, S. G., Wenk, M. R., Bateman, R. J., Morris, J. C., and Martins, R. N., “Plasma Phospholipid and Sphingolipid Alterations in Presenilin1 Mutation Carriers: A Pilot Study.”, J Alzheimers Dis, vol. 50, no. 3, pp. 887-94, 2016.
N
G. M. Babulal, Stout, S. H., Head, D., Holtzman, D. M., Fagan, A. M., Morris, J. C., and Roe, C. M., “Neuropsychiatric Symptoms and Alzheimer's Disease Biomarkers Predict Driving Decline: Brief Report.”, J Alzheimers Dis, vol. 58, no. 3, pp. 675-680, 2017.
H
J. M. Castellano, Kim, J., Stewart, F. R., Jiang, H., DeMattos, R. B., Patterson, B. W., Fagan, A. M., Morris, J. C., Mawuenyega, K. G., Cruchaga, C., Goate, A. M., Bales, K. R., Paul, S. M., Bateman, R. J., and Holtzman, D. M., “Human apoE isoforms differentially regulate brain amyloid-β peptide clearance.”, Sci Transl Med, vol. 3, no. 89, p. 89ra57, 2011.
E
D. Head, Bugg, J. M., Goate, A. M., Fagan, A. M., Mintun, M. A., Benzinger, T., Holtzman, D. M., and Morris, J. C., “Exercise Engagement as a Moderator of the Effects of APOE Genotype on Amyloid Deposition.”, Arch Neurol, vol. 69, no. 5, pp. 636-43, 2012.
D
G. M. Babulal, Chen, S., Williams, M. M., Trani, J. - F., Bakhshi, P., Chao, G. L., Stout, S. H., Fagan, A. M., Benzinger, T. L. S., Holtzman, D. M., Morris, J. C., and Roe, C. M., “Depression and Alzheimer's Disease Biomarkers Predict Driving Decline.”, J Alzheimers Dis, vol. 66, no. 3, pp. 1213-1221, 2018.
C
J. Timsina, Gomez-Fonseca, D., Wang, L., Do, A., Western, D., Álvarez, I., Aguilar, M., Pastor, P., Henson, R. L., Herries, E., Xiong, C., Schindler, S. E., Fagan, A. M., Bateman, R. J., Farlow, M., Morris, J. C., Perrin, R., Moulder, K., Hassenstab, J., Chhatwal, J., Mori, H., Sung, Y. Ju, and Cruchaga, C., “Comparative Analysis of Alzheimer's Disease Cerebrospinal Fluid Biomarkers Measurement by Multiplex SOMAscan Platform and Immunoassay-Based Approach.”, J Alzheimers Dis, vol. 89, no. 1, pp. 193-207, 2022.
A. P. Ingber, Hassenstab, J., Fagan, A. M., Benzinger, T. L. S., Grant, E. A., Holtzman, D. M., Morris, J. C., and Roe, C. M., “Cerebrospinal Fluid Biomarkers and Reserve Variables as Predictors of Future "Non-Cognitive" Outcomes of Alzheimer's Disease.”, J Alzheimers Dis, vol. 52, no. 3, pp. 1055-64, 2016.
P. Lewczuk, Matzen, A., Blennow, K., Parnetti, L., Molinuevo, J. Luis, Eusebi, P., Kornhuber, J., Morris, J. C., and Fagan, A. M., “Cerebrospinal Fluid Aβ42/40 Corresponds Better than Aβ42 to Amyloid PET in Alzheimer's Disease.”, J Alzheimers Dis, vol. 55, no. 2, pp. 813-822, 2017.
A
J. C. Morris, Roe, C. M., Xiong, C., Fagan, A. M., Goate, A. M., Holtzman, D. M., and Mintun, M. A., “APOE predicts amyloid-beta but not tau Alzheimer pathology in cognitively normal aging.”, Ann Neurol, vol. 67, no. 1, pp. 122-31, 2010.